Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has been assigned an average rating of “Buy” from the nine ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and three have given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $11.00.
A number of equities analysts have recently issued reports on the stock. Wedbush reduced their target price on shares of Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating on the stock in a research report on Wednesday. Canaccord Genuity Group started coverage on shares of Aclaris Therapeutics in a report on Tuesday, September 1st. They issued a “buy” rating and a $10.00 price target for the company. Wall Street Zen raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 24th. Craig Hallum set a $9.00 price objective on shares of Aclaris Therapeutics in a research report on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Aclaris Therapeutics in a report on Wednesday.
Get Our Latest Stock Analysis on Aclaris Therapeutics
Aclaris Therapeutics News Roundup
Here are the key news stories impacting Aclaris Therapeutics this week:
- Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.61 from $0.62 and its FY2027 estimate to a loss of $0.55 from $0.60. The firm also improved its quarterly 2027 forecasts, reflecting expectations for somewhat lower losses. HC Wainwright maintained a Buy rating and a $16 price target, substantially above ACRS’s recent trading level. HC Wainwright analyst estimates
- Positive Sentiment: HC Wainwright separately reaffirmed its Buy rating, reinforcing the analyst’s constructive view of Aclaris’s pipeline and longer-term prospects. HC Wainwright Reaffirms Buy Rating for Aclaris Therapeutics
- Neutral Sentiment: Aclaris discussed ATI-052 proof-of-concept results in atopic dermatitis and asthma. The update highlights ongoing pipeline development, but the available report does not provide enough detail to assess the results’ likely commercial or regulatory impact. Aclaris ATI-052 proof-of-concept results
- Negative Sentiment: Wedbush issued a pessimistic forecast for ACRS’s stock price, creating a counterweight to HC Wainwright’s bullish outlook and potentially contributing to weaker investor sentiment. Wedbush Issues Pessimistic Forecast for Aclaris Therapeutics
Aclaris Therapeutics Trading Down 0.5%
Shares of Aclaris Therapeutics stock opened at $3.97 on Friday. The stock has a market capitalization of $555.09 million, a price-to-earnings ratio of -6.84 and a beta of 0.87. Aclaris Therapeutics has a 1-year low of $2.10 and a 1-year high of $6.60. The firm’s 50-day moving average price is $4.88 and its two-hundred day moving average price is $4.52.
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%. The company had revenue of $1.63 million for the quarter, compared to analysts’ expectations of $1.38 million. As a group, equities research analysts predict that Aclaris Therapeutics will post -0.62 EPS for the current year.
Institutional Investors Weigh In On Aclaris Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Sei Investments Co. bought a new stake in Aclaris Therapeutics during the 1st quarter worth about $814,000. Bank of New York Mellon Corp bought a new position in shares of Aclaris Therapeutics in the 2nd quarter valued at about $1,495,000. Dimensional Fund Advisors LP boosted its stake in shares of Aclaris Therapeutics by 88.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 511,461 shares of the biotechnology company’s stock valued at $1,914,000 after purchasing an additional 240,611 shares during the last quarter. Palo Alto Investors LP bought a new position in shares of Aclaris Therapeutics in the 2nd quarter valued at about $8,535,045. Finally, Kalehua Capital Management LLC acquired a new stake in shares of Aclaris Therapeutics during the 1st quarter worth approximately $6,871,000. Institutional investors own 98.34% of the company’s stock.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.
Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.
Featured Stories
- Five stocks we like better than Aclaris Therapeutics
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
